# LifeMD's AT&T bet: free users to paying patients

> LifeMD partners with AT&T to reach 100 million customers, but the path from free membership to paid services remains unproven.
- Title: LifeMD's AT&T bet: free users to paying patients | Shortify
- Summary: LifeMD partners with AT&T to reach 100 million customers, but the path from free membership to paid services remains unproven. LifeMD's profitability depends…
- Keywords: lifemd, lfmd, at&t, partnership, telehealth, customer acquisition, glp-1 therapies, weight management, conversion rates, profitability, equity dilution, cash burn
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/lifemd-lfmd-secures-att-partnership-can-free-memberships-produce-paying-patients
- Author: Newsdesk
- Published: 2026-09-21T15:08:18+00:00
- Read time: 3 min
- Topics: lifemd, lfmd, at&t, partnership, telehealth, customer acquisition, glp-1 therapies, weight management, conversion rates, profitability, equity dilution, cash burn
## LifeMD grows subscribers but revenue falls
LifeMD reported Q2 2026 revenue of $47.28 million, down 4% year-over-year, despite adding 20% more subscribers to reach 356,000 total. The company is shifting toward higher-margin GLP-1 therapies and longer memberships.
## Margins improve despite subscriber shift
Gross margin expanded to 89% in Q2 2026 from 86% in the prior year, showing the core telehealth model remains profitable even as the company transitions its product mix and customer acquisition strategy.
## AT&T partnership launches September 2026
LifeMD announced a partnership with AT&T on September 15, 2026, offering free memberships to eligible AT&T customers while charging separately for visits ($29-$79) and prescriptions. Initial rollout covers 11 states reaching 29 million customers.
## Partnership waives $228 annual membership fee
AT&T customers get free access to LifeMD's platform, eliminating the $19 monthly membership fee. Revenue must come from visit fees and prescriptions, creating a two-stage monetization challenge: enrollment doesn't guarantee paid utilization.
## Per-lead fee structure remains secret
LifeMD will pay AT&T a fixed fee per lead, but the SEC filing doesn't disclose the amount or any minimum commitments. This creates material uncertainty around true acquisition costs and partnership profitability.
## Nationwide expansion planned for January 2027
The 11-state pilot reaching 29 million customers will expand nationwide in January 2027 to reach over 100 million eligible customers. This phased approach allows LifeMD to test conversion metrics before full-scale deployment.
## One-year contract with 90-day exit clause
The partnership has a one-year initial term with automatic annual renewals, but either party can exit with 90 days' notice. This limits long-term downside if utilization disappoints but prevents LifeMD from recouping acquisition investments across multiple years.
## Management guides to Q4 profitability inflection
LifeMD projects Q4 2026 revenue of $60-$64 million with EBITDA of $3-$6 million, implying an annualized run rate of $250 million revenue and $22 million EBITDA. This assumes successful partnership ramp and customer retention.
## Partnership spending could accelerate cash burn
If LifeMD pays AT&T $5-$10 per lead and achieves a 5% enrollment rate across 29 million initial customers, the company could spend $7-$14 million on acquisition in the pilot phase alone, increasing reliance on equity sales.
## Conversion rates are the critical unknown
The partnership's success depends on converting free AT&T members to paid services at rates sufficient to justify acquisition costs. Q3 and Q4 2026 earnings will provide the first visibility into actual conversion metrics.
## Valuation hinges on three key metrics
Investors should track AT&T enrollment rates, paid utilization conversion rates, and customer acquisition cost per paying patient versus LifeMD's historical standalone CAC. If these metrics meet expectations, the partnership could drive significant multiple expansion.
## 2027 earnings estimates show wide uncertainty
Analyst consensus for 2027 ranges from negative $0.07 to positive $0.17 per share, reflecting significant uncertainty about the profitability inflection. The wide range suggests market participants are pricing in substantial execution risk.
## Equity dilution risk if spending exceeds plans
Management stated existing cash and at-the-market equity sales will fund operations for at least 12 months. If partnership acquisition spending exceeds expectations, the company will need additional equity financing, diluting existing shareholders.
## Key takeaway

LifeMD's profitability depends entirely on converting AT&T's free members into paying customers at rates that justify the acquisition costs, which won't be clear until late 2026 earnings.